149 related articles for article (PubMed ID: 38317839)
21. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
22. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
Yu L; Qiao R; Xu J; Han B; Zhong R
Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
[TBL] [Abstract][Full Text] [Related]
23. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
24. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
Feng W; He Z; Shi L; Zhu Z; Ma H
Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
[TBL] [Abstract][Full Text] [Related]
25. [Identification and Analysis of SND1 as an Oncogene and Prognostic Biomarker
for Lung Adenocarcinoma].
Zhang R; Huang H; Zhu G; Wu D; Chen C; Cao P; Ding C; Liu H; Chen J; Li Y
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):25-37. PubMed ID: 38296623
[TBL] [Abstract][Full Text] [Related]
26. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.
Wei Q; Miao T; Zhang P; Jiang B; Yan H
Front Genet; 2022; 13():984575. PubMed ID: 36159963
[No Abstract] [Full Text] [Related]
28.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
29. SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
He X; Ma Y; Huang Z; Wang G; Wang W; Zhang R; Guo G; Zhang X; Wen Y; Zhang L
Thorac Cancer; 2023 Aug; 14(23):2275-2287. PubMed ID: 37424293
[TBL] [Abstract][Full Text] [Related]
30. Identification of eIF6 as a prognostic factor that drives tumor progression and predicts arsenic trioxide efficacy in lung adenocarcinoma.
Shen Y; Zhang R; Li X
Mol Biol Rep; 2023 Feb; 50(2):1167-1180. PubMed ID: 36435920
[TBL] [Abstract][Full Text] [Related]
31. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
32. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
[TBL] [Abstract][Full Text] [Related]
33. Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
Zheng X; Li Y; Ma C; Zhang J; Zhang Y; Fu Z; Luo H
Biomed Res Int; 2020; 2020():8851437. PubMed ID: 33178836
[TBL] [Abstract][Full Text] [Related]
34. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
35. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
Front Immunol; 2022; 13():992626. PubMed ID: 36311724
[TBL] [Abstract][Full Text] [Related]
36. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of the prognostic values and immune implication of ESYT3 in lung adenocarcinoma.
Li X; Chen J; Meng J
Medicine (Baltimore); 2023 Sep; 102(35):e34557. PubMed ID: 37657044
[TBL] [Abstract][Full Text] [Related]
38. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis.
Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ
Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851
[No Abstract] [Full Text] [Related]
39. Upregulation of NDUFAF2 in Lung Adenocarcinoma Is a Novel Independent Prognostic Biomarker.
Zou K; Gao P; Xu X; Zhang W; Zeng Z
Comput Math Methods Med; 2023; 2023():2912968. PubMed ID: 36703939
[TBL] [Abstract][Full Text] [Related]
40. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]